[Side effects and toxicity of new quinolones]. / Vedl'ajsie neziadúce úcinky a toxicita novsích chinolónov.

A review paper is presented treating of problems of organotoxicity, mutagenicity, carcinogenicity and adverse effects of quinolones, as well as their interaction with other drugs. Not considering some rather sporadic exceptions, quinolones are not regarded as safe in children up to the age of 14 and in pregnant and breast-feeding women. Compared to aminoglycosides, tetracycline, chloramphenicol, rifampicin and other antibacterial chemotherapeutics, the overall toxicity of quinolones is relatively low. The questions of adverse effects upon the intestinal microflora and of tolerance of novel quinolones are also addressed. With regard to the above mentioned aspects, ofloxanice, ciprofloxacine, enoxacine, pefloxacine, norfloxacine, and fleroxacine have been most thoroughly studied. For the other recently developed quinolones reliable information is scarce. (Tab. 2, Ref. 53).

[Ofloxacin in the treatment of infections of the respiratory tract in older patients]. / Ofloxacín v liecbe infekcií dýchacích ciest u pacientov vyssieho veku.

The authors submit a brief report on the results of treatment with ofloxacin in geriatric patients. They treated a total of 26 patients aged 60 to 87 years for bronchopneumonia (17 patients), acute exacerbation of chronic bronchitis (4 patients) and other infections of the airways (5 patients). Comorbidity was recorded in 22 patients (diabetes mellitus, chronic renal insufficiency and others). Nineteen patients were cured, in four partial or substantial improvement was recorded, in three treatment failed. The authors assume that ofloxacin can be included among drugs of first choice in the treatment of pneumonia as well as of other infections of the airways in geriatric patients. In the presented group of patients it had an excellent therapeutic effect. Undesirable side-effects were not observed in any of the patients.